Literature DB >> 19223615

Antianaerobic activity of sulopenem compared to six other agents.

Lois M Ednie1, Peter C Appelbaum.   

Abstract

Agar dilution MIC methodology was used to compare the activity of sulopenem with those of amoxicillin/clavulanate, ampicillin/sulbactam, piperacillin-tazobactam, imipenem, clindamycin, and metronidazole against 431 anaerobes. Overall, MIC(50)/(90) values were as follows: sulopenem, 0.25/1.0 microg/ml; amoxicillin/clavulanate, 0.5/2.0 microg/ml; ampicillin/sulbactam, 0.5/4.0 microg/ml; piperacillin/tazobactam, 0.25/8.0 microg/ml; imipenem, 0.06/1.0 microg/ml; clindamycin, 0.25/16.0 microg/ml; and metronidazole, 1.0/4.0 microg/ml.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19223615      PMCID： PMC2681565          DOI： 10.1128/AAC.01557-08

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  12 in total

1.  Comparative antianaerobic activity of BMS 284756.

Authors:  D B Hoellman; L M Kelly; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

2.  Activity of OPT-80, a novel macrocycle, compared with those of eight other agents against selected anaerobic species.

Authors:  Kim L Credito; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2004-11       Impact factor: 5.191

3.  Beta-lactamase production and susceptibilities to amoxicillin, amoxicillin-clavulanate, ticarcillin, ticarcillin-clavulanate, cefoxitin, imipenem, and metronidazole of 320 non-Bacteroides fragilis Bacteroides isolates and 129 fusobacteria from 28 U.S. centers.

Authors:  P C Appelbaum; S K Spangler; M R Jacobs
Journal:  Antimicrob Agents Chemother       Date:  1990-08       Impact factor: 5.191

4.  In vitro activity of CP-65,207, a new penem antimicrobial agent, in comparison with those of other agents.

Authors:  T Gootz; J Retsema; A Girard; E Hamanaka; M Anderson; S Sokolowski
Journal:  Antimicrob Agents Chemother       Date:  1989-08       Impact factor: 5.191

5.  Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin.

Authors:  A Bauernfeind
Journal:  J Antimicrob Chemother       Date:  1997-11       Impact factor: 5.790

6.  Susceptibility of 539 gram-positive and gram-negative anaerobes to new agents, including RP59500, biapenem, trospectomycin and piperacillin/tazobactam.

Authors:  P C Appelbaum; S K Spangler; M R Jacobs
Journal:  J Antimicrob Chemother       Date:  1993-08       Impact factor: 5.790

7.  Characterization of a beta-lactamase from Clostridium clostridioforme.

Authors:  P C Appelbaum; S K Spangler; G A Pankuch; A Philippon; M R Jacobs; R Shiman; E J Goldstein; D M Citron
Journal:  J Antimicrob Chemother       Date:  1994-01       Impact factor: 5.790

8.  Comparative activity of ciprofloxacin, ofloxacin, sparfloxacin, temafloxacin, CI-960, CI-990, and WIN 57273 against anaerobic bacteria.

Authors:  E J Goldstein; D M Citron
Journal:  Antimicrob Agents Chemother       Date:  1992-05       Impact factor: 5.191

9.  Evaluation of two methods for rapid testing for beta-lactamase production in Bacteroides and Fusobacterium.

Authors:  P C Appelbaum; S K Spangler; M R Jacobs
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-01       Impact factor: 3.267

10.  Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.

Authors:  Kim L Credito; Lois M Ednie; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2007-10-15       Impact factor: 5.191
View more
  4 in total

1.  In Vitro Activity of Sulopenem, an Oral Penem, against Urinary Isolates of Escherichia coli.

Authors:  James A Karlowsky; Heather J Adam; Melanie R Baxter; Andrew J Denisuik; Philippe R S Lagacé-Wiens; Andrew J Walkty; Sailaja Puttagunta; Michael W Dunne; George G Zhanel
Journal:  Antimicrob Agents Chemother       Date:  2018-12-21       Impact factor: 5.191

Review 2.  Anaerobic infections: update on treatment considerations.

Authors:  Elisabeth Nagy
Journal:  Drugs       Date:  2010-05-07       Impact factor: 9.546

3.  Clinical and microbiological characteristics of Eggerthella lenta bacteremia.

Authors:  B J Gardiner; A Y Tai; D Kotsanas; M J Francis; S A Roberts; S A Ballard; R K Junckerstorff; T M Korman
Journal:  J Clin Microbiol       Date:  2014-12-17       Impact factor: 5.948

Review 4.  Sulopenem: An Intravenous and Oral Penem for the Treatment of Urinary Tract Infections Due to Multidrug-Resistant Bacteria.

Authors:  George G Zhanel; Marianna Pozdirca; Alyssa R Golden; Courtney K Lawrence; Sheryl Zelenitsky; Liam Berry; Frank Schweizer; Denice Bay; Heather Adam; Michael A Zhanel; Philippe Lagacé-Wiens; Andrew Walkty; Neal Irfan; Kurt Naber; Joseph P Lynch; James A Karlowsky
Journal:  Drugs       Date:  2022-03-16       Impact factor: 9.546
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.